Fig. 5
From: Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
Group 3 Midline RAS/MAPK tumors. a Progression-free survival (PFS) of infants with Group 3 tumors as compared with infants with other LGG (non-midline). b The molecular drivers of Group 3 as compared with other infant LGG, highlighting the enrichment for BRAF alterations in Group 3 tumors. c PFS of infant Group 3 according to BRAF status. d Overall survival (OS) of infant OPHG versus non-infant (>1–18 y) OPHG in SickKids cohort. Comparison of OS of BRAF Fused OPHG (e) and BRAFV600E mutated OPHG (f) in infants (Group 3 of infant cohort) vs children/adolescents aged 1–18 y (SickKids cohort). All p-values calculated using the log-rank test. LGG: low-grade glioma
